A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus

AIMS: This study investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), which is a novel, oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese participants with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: This phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Ryosuke, Furihata, Kenichi, Ichikawa, Yoshihiko, Nakazuru, Yoshiomi, Bergman, Arthur, Gorman, Donal N., Saxena, Aditi R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107991/
https://www.ncbi.nlm.nih.gov/pubmed/36433713
http://dx.doi.org/10.1111/dom.14928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107991/
https://www.ncbi.nlm.nih.gov/pubmed/36433713
http://dx.doi.org/10.1111/dom.14928

Ejemplares similares